Transwell assay revealed that reduced SRGN levels decreased HCC cell migration, while CRISPLD2 overexpression partially restored migration in SRGN-suppressed cells (Figure 8L, M, N; Supplementary Figure 10E). Here, CRISPLD2 is linked to hepatocellular carcinoma.